NASDAQ:NUVL Nuvalent (NUVL) Stock Price, News & Analysis $123.96 0.00 (0.00%) As of 07/16/2026 Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock About Nuvalent Stock (NASDAQ:NUVL) View Price History Chart DataSkip Price History Chart 1 Day 5 Days 30 Days 90 Days 1 Year Advanced 1 Day 1 Day 5 Days 30 Days 90 Days 1 Year Advanced Show volume Show extended hours Get Nuvalent alerts:Sign Up Key Stats Today's Range$123.96▼$123.9650-Day Range$88.49▼$123.9652-Week Range$71.13▼$123.99VolumeN/AAverage Volume1.93 million shsMarket Capitalization$9.79 billionP/E RatioN/ADividend YieldN/APrice Target$127.73Consensus RatingHold Company Overview Nuvalent, Inc. (NASDAQ:NUVL) is a clinical-stage precision oncology company focused on the discovery, development and commercialization of targeted therapies for patients with genetically defined cancers. Founded in 2019 and headquartered in San Diego, California, Nuvalent applies structure-guided drug design to develop small molecule inhibitors that address key oncogenic drivers. The company’s research platform integrates insights from cancer biology, medicinal chemistry and translational science to create therapies with differentiated selectivity and potency against validated targets. Nuvalent’s lead pipeline candidates include NVL-520, a highly selective RET inhibitor designed to minimize off-target effects, and NVL-655, a potent covalent inhibitor targeting KRAS G12D mutations. These assets are being evaluated in multicenter Phase 1/2 clinical trials across the United States and Europe, with early data demonstrating favorable safety profiles and preliminary signs of clinical activity in patients with RET-driven and KRAS-mutant solid tumors. In addition to these core programs, Nuvalent continues to leverage its structure-based approach to advance discovery efforts and expand its portfolio into other oncogenic targets. The company conducts its operations primarily in North America, supported by strategic collaborations and investigator-led studies in international research centers. Under the leadership of President and Chief Executive Officer Bill Haney, Nuvalent has assembled a management team with extensive experience in oncology drug development, regulatory affairs and commercial planning. The organization remains committed to translating cutting-edge science into precision medicines that address unmet needs in cancer therapy.AI Generated. May Contain Errors. Read More Nuvalent Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks47th Percentile Overall ScoreNUVL MarketRank™: Nuvalent scored higher than 47% of companies evaluated by MarketBeat, and ranked 580th out of 834 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion2.3 / 5Analyst RatingHold Consensus RatingNuvalent has received a consensus rating of Hold. The company's average rating score is 2.15, and is based on no strong buy ratings, 4 buy ratings, 15 hold ratings, and 1 sell rating.Upside/DownsideThe consensus price target for Nuvalent is close to its current price, suggesting limited near-term upside or downside.Amount of Analyst CoverageNuvalent has been the subject of 15 research reports in the past 90 days, demonstrating strong analyst interest in this stock.Read more about Nuvalent's stock forecast and price target. Earnings and Valuation0.6 / 5Proj. Earnings GrowthGrowing Earnings GrowthEarnings for Nuvalent are expected to grow in the coming year, from ($5.74) to ($3.99) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Nuvalent is -20.46, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Nuvalent is -20.46, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioNuvalent has a P/B Ratio of 7.77. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.Read more about Nuvalent's valuation and earnings. Short Interest5.0 / 5Short Interest LevelHealthy Percentage of Shares Shorted0.95% of the float of Nuvalent has been sold short.Short Interest Ratio / Days to CoverNuvalent has a short interest ratio ("days to cover") of 0.45, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Nuvalent has recently decreased by 75.39%, indicating that investor sentiment is improving significantly. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldNuvalent does not currently pay a dividend.Dividend GrowthNuvalent does not have a long track record of dividend growth. News and Social Media2.5 / 5News Sentiment1.05 News SentimentNuvalent has a news sentiment score of 1.05. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.92 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 5 news articles for Nuvalent this week, compared to 6 articles on an average week.Search InterestOnly 1 people have searched for NUVL on MarketBeat in the last 30 days. This is a decrease of 0% compared to the previous 30 days. Company Ownership1.6 / 5Insider TradingSelling Shares Insider Buying vs. Insider SellingIn the past three months, Nuvalent insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $13,358,939.00 in company stock.Percentage Held by Insiders5.02% of the stock of Nuvalent is held by insiders.Percentage Held by Institutions97.26% of the stock of Nuvalent is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about Nuvalent's insider trading history. Receive NUVL Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Nuvalent and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. NUVL Stock News HeadlinesBRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations: Personalis, Inc. (Nasdaq – PSNL), Distribution Solutions Group, Inc. (Nasdaq – DSGR), Cross Country Healthcare, Inc. (Nasdaq – CCRN), Nuvalent, Inc. (Nasdaq – NUVL)July 21, 2026 | globenewswire.comNuvalent, Inc. (NASDAQ:NUVL) Given Consensus Rating of "Hold" by BrokeragesJuly 20, 2026 | americanbankingnews.comBuy this stock todayMarc Chaikin, founder of Chaikin Analytics, is sharing a strategy he calls 'Sell This, Buy That' - a way to move out of overpriced AI stocks before the tech trade breaks down and into lesser-known names with real potential to challenge the Mag 7. One pick he calls 'an upgrade to Tesla stock' is a little-known company that just inked a partnership with Nvidia, positioning it ahead of Tesla in the autonomous vehicle race.July 27 at 1:00 AM | Chaikin Analytics (Ad)Nuvalent (NASDAQ:NUVL) Upgraded to Sell at Wall Street ZenJuly 18, 2026 | americanbankingnews.comNuvalent Analyst Ratings and Price Targets | NASDAQ:NUVL | BenzingaJuly 17, 2026 | benzinga.comNuvalent (NASDAQ:NUVL) Insider Sells 2,111 SharesJuly 11, 2026 | insidertrades.comNuvalent (NASDAQ:NUVL) CEO Sells 30,000 Shares of StockJuly 9, 2026 | insidertrades.comAlexandra Balcom Sells 11,430 Shares of Nuvalent (NASDAQ:NUVL) StockJuly 7, 2026 | insidertrades.comSee More Headlines NUVL Stock Analysis - Frequently Asked Questions How have NUVL shares performed this year? Nuvalent's stock was trading at $100.59 on January 1st, 2026. Since then, NUVL shares have increased by 23.2% and is now trading at $123.96. How were Nuvalent's earnings last quarter? Nuvalent, Inc. (NASDAQ:NUVL) released its quarterly earnings data on Thursday, May, 7th. The company reported ($1.39) EPS for the quarter, missing the consensus estimate of ($1.35) by $0.04. When did Nuvalent IPO? Nuvalent (NUVL) raised $180 million in an initial public offering on Wednesday, July 28th 2021. The company issued 10,612,500 shares at a price of $16.00-$18.00 per share. Who are Nuvalent's major shareholders? Top institutional shareholders of Nuvalent include FNY Investment Advisers LLC (0.14%), Tema ETFs LLC (0.05%), Handelsbanken Fonder AB (0.02%) and GAMMA Investing LLC. Insiders that own company stock include Andrew A F Hack, Matthew Shair, James Richard Porter, Alexandra Balcom, Henry E Pelish, Deborah Ann Miller, Christopher Durant Turner, Darlene Noci and Emily Conley. View institutional ownership trends. How do I buy shares of Nuvalent? Shares of NUVL stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of Nuvalent own? Based on aggregate information from My MarketBeat watchlists, some other companies that Nuvalent investors own include Humana (HUM), NVIDIA (NVDA), Broadcom (AVGO), Meta Platforms (META), American Water Works (AWK), Arista Networks (ANET) and e.l.f. Beauty (ELF). Company Calendar Last Earnings5/07/2026Today7/27/2026Next Earnings (Estimated)8/06/2026Fiscal Year End12/31/2026Get Stock Alerts Health Indicator TradeSmith's Health IndicatorA long-term volatility-based measure designed for securities held 12 months or longer.Green: Strong and healthy uptrend with normal pullbacks.Yellow: Significant pullback but still within expected volatility.Red: Dropped beyond expected volatility; considered unhealthy. Green Zone (1m+) 1-Year History Jul 25 Oct 25 Jan 26 Apr 26 Jul 26 NUVL's financial health is in the Green zone, according to TradeSmith. NUVL has been in this zone for over one month. Industry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry MED - BIOMED/GENE Sub-IndustryPharmaceutical Products Current SymbolNASDAQ:NUVL CIK1861560 Webwww.nuvalent.com Phone857-357-7000FaxN/AEmployees40Year Founded2017Price Target and Rating Average Price Target for Nuvalent$127.73 High Price Target$165.00 Low Price Target$105.00 Potential Upside/Downside+3.0%Consensus RatingHold Rating Score (0-4)2.15 Research Coverage20 Analysts Profitability EPS (Trailing Twelve Months)($6.06) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-$425.38 million Net MarginsN/A Pretax MarginN/A Return on Equity-40.11% Return on Assets-35.43% Debt Debt-to-Equity RatioN/A Current Ratio16.14 Quick Ratio16.14 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value$15.95 per share Price / Book7.77Miscellaneous Outstanding Shares78,998,000Free Float75,032,000Market Cap$9.79 billion OptionableOptionable Beta1.14 Social Links The Infrastructure's Backbone: 10 Stocks Powering the AI BuildoutThe AI boom extends far beyond the biggest tech names. Discover 10 companies supplying the memory, storage, networking, semiconductor manufacturing, and power infrastructure that make AI possible. Learn where the next wave of AI investment opportunities may emerge—and the key risks investors should watch as the global AI buildout accelerates.Get This Free Report This page (NASDAQ:NUVL) was last updated on 7/27/2026 by MarketBeat.com Staff. From Our PartnersALERT: Drop these 5 stocks before the market opens tomorrow!The Wall Street Journal is already raising the alarm about a potential market crash, and Weiss Ratings researc...Weiss Ratings | SponsoredLouis Navellier: My #1 AI stock for 2026 (name & ticker inside)Louis Navellier's Stock Grader system helped him flag Nvidia before its 82,000% run and has identified the top...InvestorPlace | SponsoredTrump Takes Emergency Action - Plus Elon Musk's New VentureElon Musk has quietly launched a new venture - one that has nothing to do with rockets, EVs, or Neuralink. Tru...Altimetry | SponsoredYour $29.97 book is free todayWhy Some Traders Skip Stocks Entirely You don't need a big account to trade options. In fact, options ca...Profits Run | SponsoredReady to give options a try? Your first trade (Ticker included) -INSIDETired of trying tactic after tactic when it comes to options trades... only to be met with market noise and st...Base Camp Trading | SponsoredSPCX Warning - and Worst News for Stocks in 50 YearsGoldman Sachs and Morgan Stanley are now predicting what could be the worst news for the U.S. stock market in ...TradeSmith | SponsoredElon's new "super startup"Adam O'Dell - the analyst who recommended Palantir before it became the top S&P 500 performer - has identified...Banyan Hill Publishing | SponsoredWhere to Put $100 Before Trump's New Tech Law Rolls OutThe Financial Times says a new tech law puts America 'on the verge of a financial revolution.' Yahoo Finance e...Brownstone Research | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Nuvalent, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Nuvalent With A Colleague Link copied to clipboard. Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
